Autism, a neurodevelopmental disorder defined by the triad of impairments affecting social behaviour, communication, and imagination, has apparently become tenfold more prevalent in the last four decades (Curr. Biol. (2002) , 12, R42). There is clear evidence for genetic causation but, of the around 80 genes that have been linked to autism or to the more widely defined autistic spectrum disorders (ASDs), none accounts for a large proportion of cases, and none has a clearly established causation mechanism as yet. Only in the relatively rare cases where autism is a side effect of a chromosomal aberration, such as fragile X syndrome, can the causes be pinned down with some certainty (J.C. Darnell et al. Cell (2011), 146, 247-261) .
Since 2007, several studies have found evidence suggesting that rare copy number variations (CNVs) are linked to ASDs. Genome sequencing has shown that CNVs, typically involving the duplication or deletion of more than 1,000 DNA nucleotides, are quite common in the human genome, and those that are widespread in the population are believed to be harmless, although genome studies of cancer cells have also detected CNVs that are under suspicion of causing or helping the cancer. Researchers have estimated that the genomes of any two unrelated people will differ with respect to copy number in around 0.4% of the total number of nucleotides.
In 2010, the Autism Genome Project Consortium reported that in a sample of nearly 1,000 people with ASDs, compared with a group of matched controls, there was a significantly higher burden of rare CNVs involving functional genes. The researchers conclude that CNVs are likely to play a role in causing autism and other ASDs (Nature (2010), 466, 368-372) .
Simplex families, complex relations
Three recent papers published backto-back in Neuron have confirmed this conclusion and fleshed it out with additional insights. Two research groups used the Simons Simplex Collection, a collective of more than 1,000 families, each including exactly one member with a diagnosis on the autistic spectrum, to look for rare CNVs and particularly for those that occur in the patient for the first time (de novo) as opposed to inherited variations.
Stephan J. Sanders et al. (Neuron (Neuron (2011), 70, 863-885) and Dan Levy et al. (Neuron (2011 ), (Neuron (2011 , 70, 886-897) both report a significant excess of rare de novo CNVs in the ASD patients (the probands) compared with their unaffected siblings. While these occur in many different areas of the genome, the studies have identified six areas that show a statistically significant link with ASDs.
Among these, the area 16p11.2 is the only one that is linked to more than 1% of the cases studied. Therefore it has emerged as a promising candidate for further indepth studies, as it should be possible to find more patients with variations at this site.
A second site that holds promise for further research is 7q11.23. Deletions of this region are known to cause Williams syndrome, the symptoms of which include hypersociable behaviour. It is tantalising that deletion and duplication of this stretch of DNA are linked to the symmetrically opposite effect on social behaviour seen in Williams syndrome and ASDs. This observation clearly opens up opportunities for biochemical and animal studies into the mechanistic link between gene dosage and behaviour.
The two studies disagree on the role of inherited CNVs (which, however, were deliberately deselected by the study design, which excludes families with multiple cases of ASDs archgenpsychiatry.2011.76) give the heritability of autism as 37% (with a 95% confidence interval ranging from 8 to 84%), and for ASD 38% (14-67%).
Geneticist Richard Holt from the Wellcome Trust Centre for Human Genetics at Oxford comments on this finding: "This is an important study, especially given its size and the method of ascertainment of individuals with autism or ASD. While it should be viewed in the light of previous twin studies, if we accept the numbers from this study alone the significant decrease in the estimated genetic component may help explain the difficulties experienced in identifying the genes underlying autism."
However, this still leaves space for genetic causes, and even some of the non-inherited cases may arise from Among the elusive genetic causes for autism, copy number variations are emerging as an important factor. Testing for these might help parents determine the risk of recurrence. Michael Gross reports.
Copy numbers count for autism
Mind image: Autism is characterized by a triad of impairments to social behaviour, communication and imagination. One school of thought claims that individuals with autism lack a 'theory of mind', implying that they don't have a concept of themselves and other people as distinct, thinking personalities with their own beliefs, desires, etc. (Photo: N.H. Gross.)
de novo change to genes, such as the CNVs. Holt concludes that "the study by Hallmayer et al. itself still points to a sizeable genetic contribution, and over the last decade the search for genetic factors for autism has met with significant success. Given their variance from previous studies, it will be interesting to see if these estimates are replicated in future work."
Girls' and boys' networks
One other important question on which the two recent CNV studies diverge is the gender asymmetry. Autism and ASDs affect many more boys than girls, and simple genetic explanations such as recessive genes on the X chromosome (which explains the asymmetry in haemophilia) have been ruled out. The analysis of these clusters revealed that many of the processes likely to be perturbed by the CNVs identified by Levy et al. are linked to "the development and maturation of synaptic contacts in the brain," the authors write. Specifically, their analysis links adhesive proteins like neurexin and neuroligin, complex structures like the postsynaptic density, and processes like axon guidance and neuron motility to ASDs. The NETBAG analysis supports the hypothesis, the authors summarise, "that perturbed synaptogenesis is at the heart of autism."
On the gender issue, the data from Levy et al. suggest that the CNVs found in female probands are affecting a larger number of genes than in males. In addition to this, the network analysis indicates that the genes affected in female probands are more important for the functional network in which they are involved than those found affected in males. Both findings are consistent with the hypothesis that it takes a stronger genetic disruption to produce the autistic phenotype in females than in males.
Once more, additional research targeted specifically at the new candidate genes and their functional context will be necessary to confirm and flesh out these suggestions.
Testing times
The realisation that CNVs and de novo CNVs in particular play a significant role in autism raises the question of whether it would be useful to test patients for these variations. Yiping Shen et al. (Pediatrics (2010) 125, e727) have recently reported a detailed comparison of chromosome microarray (CMA) testing for CNVs Labelled autistic: Temple Grandin, one of the first generation of children to be diagnosed with autism, managed to build a successful career in animal science partly by using her own unusual sensitivity and anxieties to better understand animals. She is the author of a widely known memoir (Emergence: Labeled Autistic) and the subject of a recent HBO film in which the actor Claire Danes impersonates her. (Photo: Jonathan D. Thoreson.) (also known as array genomic comparative hybridization, or array CGH) with established diagnostic procedures including G-banded karyotype and fragile X testing.
Arrays for CMA tests are widely available, but have not yet entered general practice to the extent that generally agreed standards and references exist. Applying CMA to the entire genomes of 697 ASD patients, Shen et al. detected clinically relevant CNVs in 51 individuals (7.3%). Targeting the method at the most promising genomic regions with a smaller group of patients, they only had a discovery rate of 5.3%, but in both cases the yields are much higher than for established chromosomal tests.
These authors conclude that "CMA had the highest detection rate among clinically available genetic tests for patients with ASD". Therefore, they recommend, "CMA should be considered as part of the initial diagnostic evaluation of patients with ASD". The International Standard Cytogenomic Array (ISCA) consortium conducted a literature review and came to the same conclusion (Am. J. Hum. Genet. (2010) 86, 749) .
Still, the analysis by Shen et al. detected clinically relevant CNVs in only 7.3% of the ASD patients tested, and the specific significance of those found remains uncertain. As none of the diagnostic results suggests any treatment options, there is no immediate benefit to the patients. They may benefit indirectly in the long term, as more data accumulate and scientists gain a better understanding. Patients' families may benefit from finding out whether the specific case is associated with a de novo event or an inherited variation, which can drastically change the recurrence risk for future offspring of both the parents and unaffected siblings.
Clinical testing may in the long term also help to clarify the boundaries of the autistic spectrum and get a more reliable measure of its prevalence. An indication regarding the extent to which these issues are still in flow has emerged recently with a study conducted in South Korea which claimed a surprisingly high prevalence of ASD of 2.64% (3.74% for boys and 1.47% for girls), based on a screening of over 55,000 children aged 7 to 12 (Am. J. Psychiatry, doi: 10.1176 Psychiatry, doi: 10. /appi. ajp.2011 .
Young Shin Kim and co-workers at Yale went through a case identification process involving several steps and addressing the entire population of 7-to 12-year-olds in the community they studied. An initial screening covering both regular schools and special-needs schools yielded around 2,000 potential candidates, of whom 286 were assessed for ASD. Of these assessments, 201 returned a positive diagnosis for ASD. As there were inevitable losses along the way of families who didn't respond or failed to consent to the assessment, the authors have had to use statistical extrapolation to arrive at the reported prevalence rates.
Beyond statistical uncertainties, these findings raise all kinds of questions as to where to draw the line between ASD and 'normal', whether the condition is still widely underdiagnosed, and whether prevalence is still increasing.
Nearly seventy years after Leo Kanner first recognised and described autism, its scientific understanding is still very much at the beginning.
Michael Gross is a science writer based at Oxford. He can be contacted via his web page at www.michaelgross.co.uk What are brown algae? Brown algae or brown seaweeds are the dominant organisms in many of the world's coastal regions, where they are responsible for the bulk of primary production, often forming extensive undersea forests that host a high level of biodiversity. From an evolutionary point of view, brown algae are members of the stramenopiles (or heterokonts), a group that has been evolving independently of the well-studied animal, fungal and green plant lineages for over a billion years. As a result of this unique evolutionary history, these organisms exhibit many novel features. For example, they represent one of a very limited number of eukaryotic groups that have independently evolved complex multicellularity. Brown algae also exhibit some remarkable characteristics in terms of their cell biology; cytokinesis, for example, having features typical of both animals (centrosomes) and green plants (centrifugal cell plate formation). Moreover, since their divergence from other eukaryotic groups, brown algae have evolved several innovative metabolic processes, making them highly interesting targets for the discovery of novel biomolecules for industrial use. There is also increasing interest in the use of brown algae as a source of biomass for fuel production due to their very rapid growth rates and the fact that cultivation does not compete with food crops for the use of arable land. The giant kelp Macrocystis pyrifera, for example, is one of the largest and most rapidly growing organisms on the planet, reaching lengths of up to 60 metres.
Has a model organism been developed to study all these interesting aspects of brown algal biology? Yes, the small, filamentous brown alga Ectocarpus was proposed as a model organism for the brown algae about seven years ago and a number of genetic and molecular tools have been developed for this organism. Available tools include a considerable amount of cDNA and small RNA sequence data,
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